Aeras eyes more India, China linkages as TB vaccine trials move forward
This article was originally published in Scrip
Executive Summary
Clinical studies for two leading tuberculosis vaccine candidates, supported by the US-headquartered organisation Aeras, have started in India, as the non-profit product development partnership looks to work with firms there and elsewhere to progress its fight against the disease.